WB 1:500-1:2000; ELISA 1:10000; Not yet tested in other applications.
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Specificity
Phospho-EphA2 (Y588) Polyclonal Antibody detects endogenous levels of EphA2 protein only when phosphorylated at Y588.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):KTyVD
Purification
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Storage
-15°C to -25°C/1 year(Do not lower than -25°C)
Concentration
1 mg/ml
MW(Observed)
130kD
Modification
Phospho
Clonality
Polyclonal
Isotype
IgG
Related Products
Secondary Antibodies
Goat Anti Mouse IgG(H+L) (HRP)
RS0001
More→
Secondary Antibodies
Goat Anti Rabbit IgG(H+L) (HRP)
RS0002
More→
Primary Antibodies
β-actin (PTR2364) Mouse mAb
YM3028
More→
Primary Antibodies
GAPDH (PTR2304) Mouse mAb
YM3029
More→
Antigen&Target Information
Immunogen:
Synthesized phospho-peptide around the phosphorylation site of human EphA2 (phospho Tyr588)
show all
Specificity:
Phospho-EphA2 (Y588) Polyclonal Antibody detects endogenous levels of EphA2 protein only when phosphorylated at Y588.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):KTyVD
This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. Mutations in this gene are the cause of certain genetically-related cataract disorders.[provided by RefSeq, May 2010],
show all
Function:
Catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,Function:Receptor for members of the ephrin-A family. Binds to ephrin-A1, -A3, -A4 and -A5.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family. Ephrin receptor subfamily.,similarity:Contains 1 protein kinase domain.,similarity:Contains 1 SAM (sterile alpha motif) domain.,similarity:Contains 2 fibronectin type-III domains.,subunit:Interacts with SLA (By similarity). Interacts with INPPL1/SHIP2.,tissue specificity:Expressed most highly in tissues that contain a high proportion of epithelial cells, e.g., skin, intestine, lung, and ovary.,
show all
Cellular Localization:
Cell membrane ; Single-pass type I membrane protein . Cell projection, ruffle membrane ; Single-pass type I membrane protein . Cell projection, lamellipodium membrane ; Single-pass type I membrane protein . Cell junction, focal adhesion . Present at regions of cell-cell contacts but also at the leading edge of migrating cells (PubMed:19573808, PubMed:20861311). Relocates from the plasma membrane to the cytoplasmic and perinuclear regions in cancer cells (PubMed:18794797). .
show all
Tissue Expression:
Expressed in brain and glioma tissue and glioma cell lines (at protein level). Expressed most highly in tissues that contain a high proportion of epithelial cells, e.g. skin, intestine, lung, and ovary.